Sectra's IPO on the Shanghai Stock Exchange Sci-Tech Innovation Board has been queried. The company already has 25 medical device products.

On April 17, Cytus Biotech Co., Ltd. (referred to as Cytus) applied for the status change of the Shanghai Stock Exchange's Sci-Tech Innovation Board listing review to "under inquiry". EB SECURITIES is its sponsor institution, planning to raise 635 million yuan. The prospectus shows that Cytus focuses on the research, production, and sales of absorbable plant-based interventional medical devices. After more than twenty years of deep cultivation, the company has systematically built five leading core technology platforms including PEG functional modification, bio-based polymer material modification, synthetic medical polymer material preparation, extracellular matrix material preparation, and self-assembled peptide material design and preparation. It has become one of the few medical device companies in China that can simultaneously deploy and operate multiple absorbable medical material platforms, forming a platform-based research and development architecture driven by "material innovation driving product innovation." Based on the above platforms, the company has formed an absorbable Innovative Medical Management device product system covering various departments such as neurosurgery, cardiovascular surgery, general surgery, orthopedics, and tumor radiology. As of the end of the reporting period, the company has 25 medical device products, many of which are domestic firsts or exclusive products, filling the technological gaps in related fields. The company's flagship product, absorbable dural sealant medical adhesive (Saibrain), solves the long-standing clinical pain points of cerebrospinal fluid leakage in neurosurgery craniotomy through a water-tight sealing mechanism, providing an innovative domestic solution and filling the domestic technological gap in the treatment field. This product has entered the National Medical Products Administration's "Innovative Medical Management Device Special Approval Program" and has been included in the Ministry of Science and Technology's "Innovative Medical Management Device Product Catalog (2018)", placing it at the forefront of international technology. The company's absorbable vascular sealing medical adhesive (Sailongning) provides a new solution for preventing postoperative blood leakage at the anastomosis site of vascular reconstruction surgery, making it the first product in the field of vascular sealing by a domestic company. It remains the only domestic brand in this field, successfully achieving "import substitution." The net proceeds from the fundraising, after deduction of issuance expenses, will be used for the following projects: Financially, the company is expected to achieve operating revenues of 379 million yuan, 331 million yuan, and 338 million yuan in the years 2023, 2024, and 2025 respectively. During the same period, the net profits are expected to be approximately 153 million yuan, 161 million yuan, and 168 million yuan respectively.